ebastine has been researched along with Hay Fever in 31 studies
Excerpt | Relevance | Reference |
---|---|---|
"Ebastine is a second-generation antihistamine which has been shown to be an effective treatment for both seasonal and perennial allergic rhinitis." | 6.44 | Ebastine in allergic rhinitis and chronic idiopathic urticaria. ( Sastre, J, 2008) |
" Furthermore, it has been shown that improved clinical efficacy can be attained with an increased dosage of 20 mg daily in comparison to the usual dosage of 10 mg/day without increasing the rate of side effects." | 2.73 | [New generation antihistamines as monotherapy or in combination. What is the relevance for daily clinical routine for allergic rhinoconjunctivitis]. ( Köberlein, J; Mösges, R, 2007) |
" Overall, all treatments were safe and well tolerated." | 2.71 | Efficacy and safety of ebastine 20 mg compared to loratadine 10 mg once daily in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled study. ( Hampel, F; Howland, W; Ratner, P; Van Bavel, J, 2004) |
"Both ebastine 20 and 10 mg were well tolerated and proved safe in the treatment of SAR." | 2.71 | A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of ebastine (20 mg and 10 mg) to loratadine 10 mg once daily in the treatment of seasonal allergic rhinitis. ( Hampel, F; Howland, W; Ratner, P; Van Bavel, J, 2004) |
"Rupatadine is a new second generation H(1)-antihistamine with once-daily dosing that may provide better control of symptoms than the currently used H(1)-receptor blockers because of its dual pharmacological profile (anti-PAF and anti-H(1))." | 2.71 | Rupatadine 10 mg and ebastine 10 mg in seasonal allergic rhinitis: a comparison study. ( Castillo, JA; De Molina, M; Guadaño, EM; Meseguer, J; Picado, C; Serra-Batlles, J; Valero, A, 2004) |
" There were also no significant differences in the percentages of patients experiencing adverse events between the ebastine with and without food groups." | 2.70 | A double-blind, placebo-controlled study of the efficacy and safety of ebastine 20 mg once daily given with and without food in the treatment of seasonal allergic rhinitis. ( Frank, H; George, G; Gillen, M; Lim, J; Rohatagi, SS, 2002) |
"when Ebastine was administered exceeded 50 pollens/cm2 per hour." | 2.70 | [Clinical efficacy of Ebastine under placebo-controlled outdoors clinical study on cedar pollinosis]. ( Asaka, H; Baba, K; Yoshida, H, 2002) |
"Ebastine is a nonsedating and selective histamine H1 receptor antagonist without anticholinergic or sedative effects at therapeutic doses." | 2.69 | Comparative clinical studies with ebastine: efficacy and tolerability. ( Luria, X, 1999) |
"Ebastine is a new histamine H1-receptor blocker that may differ in efficacy from currently used second-generation agents." | 2.68 | Comparison of ebastine to cetirizine in seasonal allergic rhinitis in adults. ( Bremard-Oury, C; Gehanno, P; Zeisser, P, 1996) |
"Ebastine was well tolerated by the majority of patients - the incidence of adverse events, including headache, dry mouth, somnolence and asthenia being similar to that reported in placebo recipients." | 2.68 | Clinical studies of the efficacy and tolerability of ebastine 10 or 20 mg once daily in the treatment of seasonal allergic rhinitis in the US. ( Storms, WW, 1996) |
"Thus, ebastine is a useful alternative treatment for seasonal allergic rhinitis." | 2.68 | Clinical efficacy of ebastine in the treatment and prevention of seasonal allergic rhinitis. ( Peláez, A, 1996) |
"Ebastine was shown to block the release of anti-IgE-induced prostaglandin D2 (PGD2) and leukotriene C4/D4 from human nasal polyp cells (IC30 values of 2." | 2.68 | Overview of allergic mechanisms. Ebastine has more than an antihistamine effect. ( Bousquet, J; Bremard-Oury, C; Campbell, A; Crampette, L; Michel, FB, 1996) |
"Ebastine is an H1 antihistamine." | 2.66 | A double-blind placebo-controlled study of the efficacy and tolerability of ebastine against hayfever in general practice patients. ( Ankier, SI; Warrington, SJ, 1989) |
"Ebastine is a second-generation antihistamine which has been shown to be an effective treatment for both seasonal and perennial allergic rhinitis." | 2.44 | Ebastine in allergic rhinitis and chronic idiopathic urticaria. ( Sastre, J, 2008) |
"Ebastine is a once-daily, non-sedating, selective, long-acting, second-generation antihistamine." | 2.42 | A review of the second-generation antihistamine ebastine for the treatment of allergic disorders. ( De Belder, T; Sys, L; Van Cauwenberge, P, 2004) |
"Ebastine is a potent second-generation H1-blocker that compares well with others in the class." | 2.40 | Antihistamines in severe/chronic rhinitis. ( Bousquet, J, 1998) |
"The long QT syndrome is a rare disease." | 1.33 | Long QT syndrome in a patient with allergic rhinoconjunctivitis and auto-immune diabetes: focus on the choice of anti-H1 drugs. ( Codreanu, A; de Chillou, C; Moneret-Vautrin, DA, 2006) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (3.23) | 18.7374 |
1990's | 10 (32.26) | 18.2507 |
2000's | 18 (58.06) | 29.6817 |
2010's | 2 (6.45) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Li, LS | 1 |
Guan, K | 1 |
Cui, L | 1 |
Wang, RQ | 1 |
Izumi, N | 1 |
Mizuguchi, H | 2 |
Umehara, H | 1 |
Ogino, S | 1 |
Fukui, H | 2 |
Sastre, J | 1 |
Bousquet, J | 4 |
Bodez, T | 1 |
Gehano, P | 1 |
Klossek, JM | 1 |
Liard, F | 1 |
Neukirch, F | 1 |
Le Gal, M | 1 |
Janin, N | 1 |
Allaf, B | 1 |
Kitamura, Y | 1 |
Ogishi, H | 1 |
Kuroda, W | 1 |
Hattori, M | 1 |
Takeda, N | 1 |
Frank, H | 1 |
Gillen, M | 1 |
Rohatagi, SS | 1 |
Lim, J | 1 |
George, G | 1 |
Ratner, P | 4 |
Hampel, F | 3 |
Gispert, J | 2 |
Lund, VJ | 1 |
van Cauwenberge, P | 2 |
Bremard-Oury, C | 3 |
Mounedji, N | 1 |
Stevens, MT | 1 |
El-Akkad, T | 1 |
Van Bavel, J | 2 |
Howland, W | 2 |
Guadaño, EM | 1 |
Serra-Batlles, J | 1 |
Meseguer, J | 1 |
Castillo, JA | 1 |
De Molina, M | 1 |
Valero, A | 1 |
Picado, C | 1 |
De Belder, T | 1 |
Sys, L | 1 |
Falqués, M | 1 |
Chuecos, F | 1 |
Esbrí, R | 1 |
Peris, F | 1 |
Luria, X | 2 |
Rosales, MJ | 1 |
Moneret-Vautrin, DA | 1 |
de Chillou, C | 1 |
Codreanu, A | 1 |
Mösges, R | 1 |
Köberlein, J | 1 |
Gehanno, P | 2 |
Zeisser, P | 1 |
Storms, WW | 1 |
Cohen, B | 1 |
Peláez, A | 1 |
Conde Hernández, DJ | 1 |
Palma Aqilar, JL | 1 |
Delgado Romero, J | 1 |
Campbell, A | 1 |
Michel, FB | 1 |
Crampette, L | 1 |
Volkerts, ER | 1 |
Il'ina, NI | 1 |
Balabolkin, II | 1 |
Blokhin, BM | 1 |
Goriachkina, LA | 1 |
Kolganova, NA | 1 |
Pampura, AN | 1 |
Sidorenko, IV | 1 |
Ratner, PH | 1 |
Lim, JC | 1 |
Georges, GC | 1 |
Asaka, H | 1 |
Yoshida, H | 1 |
Baba, K | 1 |
Ankier, SI | 1 |
Warrington, SJ | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Nasal Ocular Reflexes Contribute to Eye Symptoms in Patients With Allergic Rhinitis[NCT00117832] | 20 participants | Interventional | 2005-03-31 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
4 reviews available for ebastine and Hay Fever
Article | Year |
---|---|
Ebastine in allergic rhinitis and chronic idiopathic urticaria.
Topics: Animals; Butyrophenones; Chronic Disease; Histamine H1 Antagonists; Humans; Piperidines; Rhinitis, A | 2008 |
A review of the second-generation antihistamine ebastine for the treatment of allergic disorders.
Topics: Anti-Allergic Agents; Asthma; Butyrophenones; Clinical Trials as Topic; Histamine H1 Antagonists, No | 2004 |
Meta-analysis of the efficacy of ebastine 20 mg compared to loratadine 10 mg and placebo in the symptomatic treatment of seasonal allergic rhinitis.
Topics: Adult; Butyrophenones; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Male; Mul | 2005 |
Antihistamines in severe/chronic rhinitis.
Topics: Butyrophenones; Histamine H1 Antagonists; Humans; Piperidines; Rhinitis, Allergic, Perennial; Rhinit | 1998 |
19 trials available for ebastine and Hay Fever
Article | Year |
---|---|
[Effects of double-dose antihistamine or combined therapy in allergic rhinitis].
Topics: Administration, Intranasal; Anti-Allergic Agents; Butyrophenones; Double-Blind Method; Drug Therapy, | 2018 |
Implementation of guidelines for allergic rhinitis in specialist practices. A randomized pragmatic controlled trial.
Topics: Adolescent; Adult; Butyrophenones; Female; Histamine H1 Antagonists; Humans; Male; Piperidines; Prac | 2009 |
A double-blind, placebo-controlled study of the efficacy and safety of ebastine 20 mg once daily given with and without food in the treatment of seasonal allergic rhinitis.
Topics: Adolescent; Adult; Aged; Butyrophenones; Child; Double-Blind Method; Female; Food-Drug Interactions; | 2002 |
Efficacy of ebastine in the control of nasal congestion associated with allergic rhinitis.
Topics: Adult; Ambrosia; Butyrophenones; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hist | 2003 |
Implementation of guidelines for seasonal allergic rhinitis: a randomized controlled trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Anti-Allergic Agents; Butyrophenones; Conju | 2003 |
Efficacy and safety of ebastine 20 mg compared to loratadine 10 mg once daily in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Butyrophenones; Child; Double-Blind Method; Female; Histamine H1 Antagonist | 2004 |
A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of ebastine (20 mg and 10 mg) to loratadine 10 mg once daily in the treatment of seasonal allergic rhinitis.
Topics: Administration, Oral; Butyrophenones; Cross-Over Studies; Dose-Response Relationship, Drug; Double-B | 2004 |
Rupatadine 10 mg and ebastine 10 mg in seasonal allergic rhinitis: a comparison study.
Topics: Adolescent; Adult; Analysis of Variance; Anti-Allergic Agents; Butyrophenones; Cyproheptadine; Doubl | 2004 |
[New generation antihistamines as monotherapy or in combination. What is the relevance for daily clinical routine for allergic rhinoconjunctivitis].
Topics: Adrenal Cortex Hormones; Adult; Butyrophenones; Conjunctivitis; Drug Combinations; Female; Germany; | 2007 |
Comparison of ebastine to cetirizine in seasonal allergic rhinitis in adults.
Topics: Adult; Butyrophenones; Cetirizine; Double-Blind Method; Female; Histamine H1 Antagonists; Humans; Ma | 1996 |
Clinical studies of the efficacy and tolerability of ebastine 10 or 20 mg once daily in the treatment of seasonal allergic rhinitis in the US.
Topics: Adolescent; Adult; Butyrophenones; Child; Double-Blind Method; Female; Histamine H1 Antagonists; Hum | 1996 |
Comparison of the efficacy of ebastine 10mg and 20mg once daily with that of cetirizine 10mg once daily in adults with seasonal allergic rhinitis. A multicentre double-blind study.
Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Butyrophenones; Cetirizine; Double-Blind Method; Fema | 1996 |
Clinical efficacy of ebastine in the treatment and prevention of seasonal allergic rhinitis.
Topics: Astemizole; Butyrophenones; Double-Blind Method; Histamine H1 Antagonists; Humans; Piperidines; Rhin | 1996 |
Comparison of azelastine nasal spray and oral ebastine in treating seasonal allergic rhinitis.
Topics: Administration, Intranasal; Administration, Oral; Adolescent; Adult; Butyrophenones; Female; Histami | 1995 |
Overview of allergic mechanisms. Ebastine has more than an antihistamine effect.
Topics: Adolescent; Adult; Allergens; Butyrophenones; Cross-Over Studies; Double-Blind Method; Female; Granu | 1996 |
Comparative clinical studies with ebastine: efficacy and tolerability.
Topics: Adolescent; Adult; Aged; Butyrophenones; Child; Double-Blind Method; Electrocardiography; Electrocar | 1999 |
Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis. The Ebastine Study Group.
Topics: Adolescent; Adult; Aged; Butyrophenones; Child; Double-Blind Method; Female; Histamine H1 Antagonist | 2000 |
[Clinical efficacy of Ebastine under placebo-controlled outdoors clinical study on cedar pollinosis].
Topics: Adult; Butyrophenones; Female; Histamine H1 Antagonists; Humans; Male; Piperidines; Pollen; Rhinitis | 2002 |
A double-blind placebo-controlled study of the efficacy and tolerability of ebastine against hayfever in general practice patients.
Topics: Adult; Butyrophenones; Double-Blind Method; Female; Histamine H1 Antagonists; Humans; Male; Piperidi | 1989 |
8 other studies available for ebastine and Hay Fever
Article | Year |
---|---|
Analysis of disease-dependent sedative profiles of H(1)-antihistamines by large-scale surveillance using the visual analog scale.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asthma; Butyrophenones; Cetirizine; Child; Chlorpheniram | 2008 |
Preseasonal prophylactic treatment with antihistamines suppresses IL-5 but not IL-33 mRNA expression in the nasal mucosa of patients with seasonal allergic rhinitis caused by Japanese cedar pollen.
Topics: Butyrophenones; Cryptomeria; Female; Histamine Antagonists; Humans; Interleukin-33; Interleukin-5; I | 2012 |
[Antihistamines. How safe are they?].
Topics: Butyrophenones; Electrocardiography; Histamine H1 Antagonists; Humans; Piperidines; Rhinitis, Allerg | 2002 |
[In seasonal and perennial rhinitis. Superiority to standard H1 blockers].
Topics: Anti-Allergic Agents; Butyrophenones; Cetirizine; Double-Blind Method; Histamine H1 Antagonists; His | 2003 |
[Antihistaminics. Side effects also after raising dosage at the placebo level].
Topics: Anti-Allergic Agents; Benzimidazoles; Butyrophenones; Cetirizine; Double-Blind Method; Histamine H1 | 2003 |
Long QT syndrome in a patient with allergic rhinoconjunctivitis and auto-immune diabetes: focus on the choice of anti-H1 drugs.
Topics: Adolescent; Adrenergic beta-Antagonists; Anti-Asthmatic Agents; Butyrophenones; Cetirizine; Conjunct | 2006 |
Comparison of ebastine with cetirizine.
Topics: Adult; Butyrophenones; Cetirizine; Histamine H1 Antagonists; Humans; Piperidines; Rhinitis, Allergic | 1997 |
[Ebastine in the treatment of seasonal allergic rhinitis].
Topics: Administration, Oral; Adolescent; Adult; Aged; Butyrophenones; Child; Female; Follow-Up Studies; His | 1998 |